Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Hansa Biopharma Announces Reimbursement in Italy for Idefirix as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has announced that the […]
BRIM Biotechnology Receives FDA Orphan Drug Designation for BRM424 to Treat Neurotrophic Keratitis
BRIM Biotechnology is pleased to announce that the US Food and Drug Administration (FDA) has […]
ExPLoRNA Therapeutics Receives Funding to Advance its Novel mRNA Technology
ExPLoRNA Therapeutics, a Polish biotech company revolutionizing mRNA vaccines and therapeutics with unprecedented translational efficiency, […]
Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma
Accord Healthcare, a leading generic pharmaceutical company, has added Bendamustine Lyo Injection to its line […]
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
Ascletis Pharma has announced that China National Medical Products Administration (NMPA) has approved the Investigational […]
PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing
PacBio, a leading developer of high-quality, highly accurate sequencing solutions, has announced its HiFi sequencing […]
Bone Health Technologies announces positive Topline Results from Groundbreaking Pivotal Trial of Non-pharmacological Treatment for Osteopenia
Bone Health Technologies (BHT), a leading innovator of technologies for improving bone health, has announced […]
Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced […]
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that it has dosed the first patient in […]
Alnylam Announces Approval of AMVUTTRA® in Brazil for the Treatment of Transtirretina-Mediated Hereditary Amyloidosis in Adults
Alnylam Pharmaceuticals, a leading RNAi therapy company, has announced that the National Health Surveillance Agency […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more